The Emerging Role of Biosimilars: New Opportunities for Sites & Patients

Register now

August 09, 2016

Register Save to Calendar

Course Description

In today’s clinical research environment, biosimilars present long-term study opportunities for investigators. Citeline® has reported 350 biosimilars in development in 2015, which is an increase of 23% over the past year. Join us for this webinar to learn more about the biosimilar pipeline and how the demand for investigators across a wide range of therapy areas could be an opportunity waiting for sites like you! Our speakers will explain biosimilars (not to be confused with ‘generics’) and how they can increase access to biologic therapies for patients around the world. Large clinical trials are required to bring biosimilars to market, presenting immediate and long-term benefits for both sites and their patients.

Learning Objectives

  1. Recognize the global unmet need for biologics and how biosimilars can provide more cost-effective therapies.
  2. Appreciate the depth of pre-clinical testing required of biosimilars to establish similarity in safety and efficacy to their originator biologics before they are tested in humans.
  3. Identify biologics targeted for biosimilar development and therapy areas in which investigators will be needed to conduct clinical trials.
  4. Assess the immediate and long-term benefits of participation for sites and their patients.


Nigel Rulewski, MD, Head, Biosimilars Center of Excellence, Quintiles

Tracy Stewart, MBA, Director, Site & Patient Networks, Quintiles